Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational study compares nivolumab and ipilimumab plus chemotherapy in NSCLC, suggesting treatments vary by PD-L1 TPS.

Nivolumab and ipilimumab therapy improved overall survival in advanced NSCLC with low PD-L1 expression.
In patients with PD-L1 TPS of 1-20%, median overall survival was 12.0 months for single-therapy compared to dual-therapy, p=0.022.
Retrospective, observational study evaluated treatment regimens in 139 patients, distinguishing between PD-L1 TPS levels.
Findings highlight the need for tailored immunotherapy approaches based on PD-L1 expression levels in NSCLC patients.

Fukui et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark